DnB Asset Management AS purchased a new stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 24,300 shares of the biopharmaceutical company’s stock, valued at approximately $9,136,000.
Several other institutional investors have also made changes to their positions in the company. Fieldpoint Private Securities LLC acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth about $130,000. FNY Partners Fund LP increased its holdings in Regeneron Pharmaceuticals by 200.0% during the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the period. Vident Investment Advisory LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $200,000. Virtu KCG Holdings LLC purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $206,000. Finally, Moors & Cabot Inc. purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $217,000. 66.63% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently commented on REGN shares. Barclays downgraded Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $450.00 to $395.00 in a report on Friday, October 20th. Canaccord Genuity restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Oppenheimer restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, September 27th. JPMorgan Chase & Co. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, November 28th. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $471.11.
Regeneron Pharmaceuticals Inc (NASDAQ REGN) opened at $374.07 on Thursday. Regeneron Pharmaceuticals Inc has a fifty-two week low of $340.09 and a fifty-two week high of $543.55. The firm has a market capitalization of $40,190.00, a price-to-earnings ratio of 33.98, a P/E/G ratio of 1.42 and a beta of 1.52. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter last year, the firm earned $3.13 earnings per share. equities analysts forecast that Regeneron Pharmaceuticals Inc will post 13.55 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://ledgergazette.com/2018/01/18/dnb-asset-management-as-buys-shares-of-24300-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.